Kidney Failure, End Stage Renal Disease, Hypotension, Cardiovascular Diseases, Patient Safety
Conditions
Keywords
Peer Mentoring, Team Training, Checklist
Brief summary
The purpose of this study is reduce episodes of intradialytic hypotension, low blood pressure during a hemodialysis session, in patients with End Stage Renal Disease (ESRD). Recruitment will take place on the clinic level rather than the patient level.
Detailed description
When a person's kidneys stop working, he or she has end-stage renal disease (ESRD). Individuals with ESRD cannot live without either dialysis therapy-in which a machine performs the functions of the kidneys-or a kidney transplant. Dialysis must remove fluid as well as toxins in the blood. People with ESRD have a high risk for death, and the usual cause is cardiovascular disease. Most people in the United States who have ESRD get hemodialysis therapy in a clinic for four hours at a time, three times a week. The stability of hemodialysis sessions varies, and many sessions become unstable from low blood pressure and other complications. Unstable dialysis sessions can result in negative symptoms, like fatigue. Dialysis instability is an important problem. Session instability is linked to injury to the heart and other organs. Patients who have unstable dialysis sessions are more likely to end up in the hospital or die than are those who have stable sessions. Session instability is preventable. The main causes of instability are removal of fluid from a patient too fast or removal of too much fluid. Session instability results from many factors: decisions made by patients, and decisions by healthcare providers. Presently, the way to best improve the stability of dialysis is not clear. Dialysis clinics approach this problem differently, and there is variation among clinics in how often hemodialysis sessions become unstable. In partnership with the National Kidney Foundation and Fresenius Medical Care North America, the investigators will test two interventions designed to increase the stability of patient dialysis. One intervention, multimodal provider education, focuses on dialysis facility care teams. It includes team training, online education, and a checklist. Another intervention, patient activation, focuses on patients. It includes peer mentoring by trained ESRD patients. Mentors will hold with other patients multimedia-aided meetings that include skills instruction and role modeling. These interventions have been successful in hospital care and in chronic disease care, and the investigators will adapt them to dialysis safety. The investigators will then conduct a study in 20 dialysis facilities in different parts of the United States. Five facilities will get the provider education only; five will get the patient activation intervention only; five will get both interventions; and five will get no interventions. The investigators will test whether session stability improves in the facilities that get either intervention over the 48-week study period. This study is expected to clarify whether these interventions can make dialysis safer for ESRD patients. This will inform hemodialysis care providers on whether to pursue provider-focused or patient-focused safety interventions, or both. People on hemodialysis will also have information to help them decide whether to become engaged in their session stability, and the intervention will help them learn how to do so.
Interventions
Patients in clinics assigned to this group will be offered peer mentoring and digital resources.
Staff in clinics assigned to this group will receive team training and a checklist.
Sponsors
Study design
Intervention model description
The study is a 2X2 factorial design, such that five facilities will get the provider education only; five will get the patient activation intervention only; five will get both interventions; and five will get no interventions.
Eligibility
Inclusion criteria
Selection is at both the clinic level and individual patient level. Clinic Inclusion Criteria: * outpatient hemodialysis facilities * at least 70 adult (\>21 years old) patients to guarantee sample size Clinic
Exclusion criteria
* facilities involved in another study * facilities in immediate jeopardy * facilities with 1-star quality ratings * facilities designated as COVID-19 isolation facilities Individual Patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dialysis Session Stability | 24 weeks | Systolic blood pressure (SBP) falling below 100 mmHg (using lowest SBP during session) if starting SBP ≥100. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dialysis Adherence - Average Weekly Minutes Missed Over Intervention Period | 24 weeks | Measured as the average number of minutes of prescribed dialysis time missed per week during intervention period (number of prescribed minutes-number of actual minutes/24 week intervention period). |
| Dialysis Adherence - Average Weekly Sessions Missed During Intervention Period | 24 weeks | Measured as the average number of missed sessions per week during the intervention period (number of prescribed sessions-number of actual sessions/24 week intervention period). |
| Patient Symptoms - Post-dialysis Recovery Time | 24 weeks | Measured at midweek session as patient recovery time after dialysis, reported on a survey item on an ordinal scale from within minutes to did not recover before the next scheduled dialysis session. Responses grouped into three categories for analysis: did not recover, recovered before reaching home, and recovered on same day of treatment. Sessions categorized as recovered before reaching home used for comparison between study arms. |
| Patient Symptoms - Symptom Burden | 24 weeks | Measured as the total number symptoms reported by the patient at each session (each symptom treated as one, then added to create total symptoms). |
| Fluid Adherence | 24 weeks | Measured by interdialytic weight gain (in Kilograms), which is the weight gained between dialysis sessions (presented as average throughout 24 week intervention period) |
| Quality of Life-KDQOL - PCS | post-intervention survey | Total score measured by adding responses on the Kidney Disease Quality of Life survey (KDQOLTM-36 Version 1). PCS (physical component summary) ranges from 7.3 - 70.1; higher scores represent better functioning. |
| Hospitalization | 24 weeks | Hospitalization rates, measured as a total number of hospital admission for any reason per total patients year (all-cause hospitalizations) |
| Mortality | 24 weeks | Mortality rates, measured as a total number of deaths due to any cause per 100 patient years during the study period (all-cause mortality). |
| Quality of Life-KDQOL - MCS | post-intervention survey | Total score measured by adding responses on the Kidney Disease Quality of Life survey (KDQOLTM-36 Version 1). MCS (mental component summary) subscale ranges from 5.8 - 69.9; higher scores represent better functioning. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| No Intervention Patients in clinic receive usual care. | 382 |
| Patient Activation This arm focuses on patients. It includes peer mentoring by trained End Stage Renal Disease (ESRD) patients. Mentors will hold 5 multimedia-aided meetings with other patients that include motivational interviewing and role modeling. | 346 |
| Provider Education This arm focuses on dialysis facility care teams. It includes team training, online education, and checklists. | 410 |
| Patient and Provider This arm includes both Patient Activation and Provider Education interventions | 293 |
| Total | 1,431 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Baseline | Death | 1 | 2 | 1 | 5 |
| Baseline | No longer receiving in-center hemodialysis | 0 | 2 | 3 | 0 |
| Baseline | Received transplant | 0 | 0 | 1 | 0 |
| Baseline | Recovered renal function | 0 | 0 | 1 | 0 |
| Baseline | Transferred out of clinic | 4 | 0 | 2 | 0 |
| Baseline | Withdrawal by Subject | 0 | 0 | 1 | 2 |
| Follow up | Death | 18 | 12 | 5 | 8 |
| Follow up | Lost to Follow-up | 1 | 2 | 3 | 1 |
| Follow up | No longer receiving in-center hemodialysis | 4 | 2 | 1 | 0 |
| Follow up | Received transplant | 4 | 1 | 0 | 1 |
| Follow up | Transferred out of clinic | 4 | 4 | 12 | 7 |
| Follow up | Withdrawal by Subject | 1 | 1 | 0 | 0 |
| Intervention | Death | 26 | 16 | 29 | 14 |
| Intervention | Lost to Follow-up | 0 | 1 | 0 | 0 |
| Intervention | No longer receiving in-center hemodialysis | 7 | 4 | 4 | 6 |
| Intervention | Received transplant | 7 | 5 | 3 | 6 |
| Intervention | Transferred out of clinic | 12 | 9 | 17 | 9 |
| Intervention | Withdrawal by Subject | 2 | 0 | 0 | 4 |
Baseline characteristics
| Characteristic | No Intervention | Total | Patient and Provider | Provider Education | Patient Activation |
|---|---|---|---|---|---|
| Age, Continuous | 65.45 years STANDARD_DEVIATION 13.92 | 62.63 years STANDARD_DEVIATION 14.27 | 61.66 years STANDARD_DEVIATION 14.7 | 59.90 years STANDARD_DEVIATION 13.36 | 63.58 years STANDARD_DEVIATION 14.72 |
| Dialysis Session Stability | 0.197 Proportion of sessions STANDARD_DEVIATION 0.215 | 0.187 Proportion of sessions STANDARD_DEVIATION 0.212 | 0.177 Proportion of sessions STANDARD_DEVIATION 0.213 | 0.175 Proportion of sessions STANDARD_DEVIATION 0.206 | 0.198 Proportion of sessions STANDARD_DEVIATION 0.212 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 71 Participants | 209 Participants | 32 Participants | 38 Participants | 68 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 307 Participants | 1170 Participants | 245 Participants | 353 Participants | 265 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 4 Participants | 52 Participants | 16 Participants | 19 Participants | 13 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 6 Participants | 24 Participants | 3 Participants | 9 Participants | 6 Participants |
| Race (NIH/OMB) Black or African American | 115 Participants | 569 Participants | 130 Participants | 233 Participants | 91 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 3 Participants | 5 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants | 42 Participants | 13 Participants | 10 Participants | 14 Participants |
| Race (NIH/OMB) White | 252 Participants | 789 Participants | 147 Participants | 157 Participants | 233 Participants |
| Sex: Female, Male Female | 163 Participants | 594 Participants | 115 Participants | 162 Participants | 154 Participants |
| Sex: Female, Male Male | 219 Participants | 837 Participants | 178 Participants | 248 Participants | 192 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 45 / 382 | 30 / 346 | 35 / 410 | 27 / 293 |
| other Total, other adverse events | 0 / 382 | 0 / 346 | 0 / 410 | 0 / 293 |
| serious Total, serious adverse events | 0 / 382 | 0 / 346 | 0 / 410 | 0 / 293 |
Outcome results
Dialysis Session Stability
Systolic blood pressure (SBP) falling below 100 mmHg (using lowest SBP during session) if starting SBP ≥100.
Time frame: 24 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| No Intervention | Dialysis Session Stability | 0.202 Proportion of sessions | Standard Deviation 0.217 |
| Patient Activation | Dialysis Session Stability | 0.199 Proportion of sessions | Standard Deviation 0.204 |
| Provider Education | Dialysis Session Stability | 0.172 Proportion of sessions | Standard Deviation 0.19 |
| Patient and Provider | Dialysis Session Stability | 0.182 Proportion of sessions | Standard Deviation 0.205 |
Dialysis Adherence - Average Weekly Minutes Missed Over Intervention Period
Measured as the average number of minutes of prescribed dialysis time missed per week during intervention period (number of prescribed minutes-number of actual minutes/24 week intervention period).
Time frame: 24 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| No Intervention | Dialysis Adherence - Average Weekly Minutes Missed Over Intervention Period | 5.23 average weekly minutes | Standard Deviation 13.48 |
| Patient Activation | Dialysis Adherence - Average Weekly Minutes Missed Over Intervention Period | 4.21 average weekly minutes | Standard Deviation 9.05 |
| Provider Education | Dialysis Adherence - Average Weekly Minutes Missed Over Intervention Period | 5.28 average weekly minutes | Standard Deviation 10.58 |
| Patient and Provider | Dialysis Adherence - Average Weekly Minutes Missed Over Intervention Period | 4.89 average weekly minutes | Standard Deviation 11.69 |
Dialysis Adherence - Average Weekly Sessions Missed During Intervention Period
Measured as the average number of missed sessions per week during the intervention period (number of prescribed sessions-number of actual sessions/24 week intervention period).
Time frame: 24 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| No Intervention | Dialysis Adherence - Average Weekly Sessions Missed During Intervention Period | 0.004 average proportion of sessions missed | Standard Deviation 0.008 |
| Patient Activation | Dialysis Adherence - Average Weekly Sessions Missed During Intervention Period | 0.008 average proportion of sessions missed | Standard Deviation 0.041 |
| Provider Education | Dialysis Adherence - Average Weekly Sessions Missed During Intervention Period | 0.028 average proportion of sessions missed | Standard Deviation 0.061 |
| Patient and Provider | Dialysis Adherence - Average Weekly Sessions Missed During Intervention Period | 0.032 average proportion of sessions missed | Standard Deviation 0.077 |
Fluid Adherence
Measured by interdialytic weight gain (in Kilograms), which is the weight gained between dialysis sessions (presented as average throughout 24 week intervention period)
Time frame: 24 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| No Intervention | Fluid Adherence | 2.12 Kg | Standard Deviation 0.87 |
| Patient Activation | Fluid Adherence | 2.18 Kg | Standard Deviation 1.18 |
| Provider Education | Fluid Adherence | 2.35 Kg | Standard Deviation 0.93 |
| Patient and Provider | Fluid Adherence | 2.34 Kg | Standard Deviation 1.01 |
Hospitalization
Hospitalization rates, measured as a total number of hospital admission for any reason per total patients year (all-cause hospitalizations)
Time frame: 24 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| No Intervention | Hospitalization | 1.55 hospitalizations per patient year |
| Patient Activation | Hospitalization | 1.15 hospitalizations per patient year |
| Provider Education | Hospitalization | 1.37 hospitalizations per patient year |
| Patient and Provider | Hospitalization | 1.23 hospitalizations per patient year |
Mortality
Mortality rates, measured as a total number of deaths due to any cause per 100 patient years during the study period (all-cause mortality).
Time frame: 24 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| No Intervention | Mortality | 16.99 Deaths per 100 patient years |
| Patient Activation | Mortality | 9.30 Deaths per 100 patient years |
| Provider Education | Mortality | 14.85 Deaths per 100 patient years |
| Patient and Provider | Mortality | 10.44 Deaths per 100 patient years |
Patient Symptoms - Post-dialysis Recovery Time
Measured at midweek session as patient recovery time after dialysis, reported on a survey item on an ordinal scale from within minutes to did not recover before the next scheduled dialysis session. Responses grouped into three categories for analysis: did not recover, recovered before reaching home, and recovered on same day of treatment. Sessions categorized as recovered before reaching home used for comparison between study arms.
Time frame: 24 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| No Intervention | Patient Symptoms - Post-dialysis Recovery Time | 0.141 Proportion session recovery before home | Standard Deviation 0.106 |
| Patient Activation | Patient Symptoms - Post-dialysis Recovery Time | 0.181 Proportion session recovery before home | Standard Deviation 0.091 |
| Provider Education | Patient Symptoms - Post-dialysis Recovery Time | 0.178 Proportion session recovery before home | Standard Deviation 0.091 |
| Patient and Provider | Patient Symptoms - Post-dialysis Recovery Time | 0.158 Proportion session recovery before home | Standard Deviation 0.108 |
Patient Symptoms - Symptom Burden
Measured as the total number symptoms reported by the patient at each session (each symptom treated as one, then added to create total symptoms).
Time frame: 24 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| No Intervention | Patient Symptoms - Symptom Burden | 0.045 Average symptoms reported per session | Standard Deviation 0.095 |
| Patient Activation | Patient Symptoms - Symptom Burden | 0.069 Average symptoms reported per session | Standard Deviation 0.154 |
| Provider Education | Patient Symptoms - Symptom Burden | 0.051 Average symptoms reported per session | Standard Deviation 0.123 |
| Patient and Provider | Patient Symptoms - Symptom Burden | 0.063 Average symptoms reported per session | Standard Deviation 0.133 |
Quality of Life-KDQOL - MCS
Total score measured by adding responses on the Kidney Disease Quality of Life survey (KDQOLTM-36 Version 1). MCS (mental component summary) subscale ranges from 5.8 - 69.9; higher scores represent better functioning.
Time frame: post-intervention survey
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| No Intervention | Quality of Life-KDQOL - MCS | 53.85 Score | Standard Deviation 8.73 |
| Patient Activation | Quality of Life-KDQOL - MCS | 52.62 Score | Standard Deviation 10.16 |
| Provider Education | Quality of Life-KDQOL - MCS | 54.58 Score | Standard Deviation 8.3 |
| Patient and Provider | Quality of Life-KDQOL - MCS | 54.89 Score | Standard Deviation 8.67 |
Quality of Life-KDQOL - PCS
Total score measured by adding responses on the Kidney Disease Quality of Life survey (KDQOLTM-36 Version 1). PCS (physical component summary) ranges from 7.3 - 70.1; higher scores represent better functioning.
Time frame: post-intervention survey
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| No Intervention | Quality of Life-KDQOL - PCS | 35.98 Score | Standard Deviation 10.05 |
| Patient Activation | Quality of Life-KDQOL - PCS | 38.01 Score | Standard Deviation 10.36 |
| Provider Education | Quality of Life-KDQOL - PCS | 39.49 Score | Standard Deviation 11.7 |
| Patient and Provider | Quality of Life-KDQOL - PCS | 36.18 Score | Standard Deviation 10.99 |